Editas Medicine Expands Senior Management Team
October 03, 2016 08:00 ET
|
Editas Medicine
-- Appoints Gerald Cox, M.D., Ph.D., as Chief Medical Officer -- -- Kenneth LeClair, Ph.D. joins as Vice President, Technical Development and Manufacturing and Semiramis Trotto joins as Vice...
Editas Medicine to Present at the Morgan Stanley Global Healthcare Conference
September 06, 2016 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present at the Morgan Stanley Global...
Editas Medicine Names Charles Albright as Chief Scientific Officer
August 22, 2016 07:30 ET
|
Editas Medicine
CAMBRIDGE, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the appointment of Charles Albright, Ph.D. as Chief...
Editas Medicine Announces Second Quarter 2016 Results and Update
August 09, 2016 16:01 ET
|
Editas Medicine
Exclusive license to high-fidelity Cas9 and Cas9 PAM variants from Massachusetts General Hospital further advances leading genome editing platform Strategic partnership with Adverum to explore...
Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye
August 09, 2016 07:05 ET
|
Editas Medicine; Adverum Biotechnologies, Inc.
-Collaboration Brings Together Vector and Ophthalmology Expertise of Adverum with Genome Editing Capabilities of Editas- MENLO PARK, Calif. and CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) --...
Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
August 03, 2016 08:00 ET
|
Editas Medicine
-- License to Engineered Forms of Cas9 Nuclease Includes High-Fidelity Cas9 and Cas9 PAM Variants -- CAMBRIDGE, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a...
Editas Medicine to Host Conference Call Discussing Second Quarter 2016 Corporate Update and Results
August 02, 2016 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors
July 29, 2016 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., July 29, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the appointment of Akshay Vaishnaw, M.D., Ph.D., to its...
Editas Medicine Announces Scientific Multi-Year Collaboration with Fondazione Telethon and Ospedale San Raffaele
July 28, 2016 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, and Fondazione Telethon and Ospedale San Raffaele, which operate a joint...
Editas Medicine to Present at Upcoming June Investor Conferences
May 24, 2016 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present company overviews at three upcoming...